Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer

  • Authors:
    • Liqiang Guo
    • Yuqiang Liu
    • Zhibo Ding
    • Wendong Sun
    • Mingzhen Yuan
  • View Affiliations

  • Published online on: October 27, 2015     https://doi.org/10.3892/ol.2015.3830
  • Pages: 385-392
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the potential mechanisms used during signal transduction by M3 muscarinic acetylcholine receptor (CHRM3) in prostate cancer. The microarray datasets of GSE3325, including 5 clinically localized primary prostate cancers and 4 benign prostate tissues, were downloaded from the Gene Expression Omnibus database. The differentially‑expressed genes (DEGs) in primary prostate cancer tissues compared with benign controls were screened using the Limma package. Gene Ontology and pathway enrichment analyses were performed using the Database for Annotation Visualization and Integrated Discovery. Next, a protein‑protein interaction (PPI) network was constructed. Additionally, microRNAs (miRNAs) associated with DEGs were predicted and miRNA‑target DEG analysis was performed using a Web‑based Gene Set Analysis Toolkit. Finally, the PPI network and the miRNA‑target DEG network were integrated using Cytoscape. In total, 224 DEGs were screened in the prostate cancer tissues, including 113 upregulated and 111 downregulated genes. CHRM3 and epidermal growth factor (EGF) were enriched in the regulation of the actin cytoskeleton. EGF and v‑myc avian myelocytomatosis viral oncogene homolog (Myc) were enriched in the mitogen‑activated protein kinase (MAPK) signaling pathway. EGF with the highest degree of connectivity was the hub node in the PPI network, and miR‑34b could interact with Myc directly in the miRNA‑target DEG network. EGF and Myc may exhibit significant roles in the progression of prostate cancer via regulation of the actin cytoskeleton and the MAPK signaling pathway. CHRM3 may activate these two pathways in prostate cancer progression. Thus, these two key factors and pathways may be crucial mechanisms during signal transduction by CHRM3 in prostate cancer.

Introduction

Prostate cancer is one of the leading causes of cancer-associated mortality in males, accounting for >240,000 new cancer cases and 28,000 fatalities annually in males in the United States (1,2). Although effective surgical and radiation treatments exist for clinically localized prostate cancer, the majority of patients with metastatic prostate cancer eventually succumb to the disease (3). Therefore, in order to develop more effective outcomes for the diagnosis and treatment of prostate cancer, articulation of the genetic underpinning and novel therapeutic targets are critically required.

Recently, the presence and function of muscarinic acetylcholine receptors (mAChRs) in the human prostate have aroused wide concern (4,5). mAChR and its ligands have been found to play key roles in regulating cellular proliferation and cancer progression (6). mAChRs are preferentially localized to the glandular epithelium of the prostate and promote the paracrine/autocrine actions within the prostate gland, which are critical for cancer cell survival, proliferation and migration (4,6,7). mAChRs consist of five distinct subtypes (M1-M5), and the M3 mAChR (also known as CHRM3) has been found to be a key member involved in prostate cancer. The stimulation of CHRM3 is strongly associated with the tumor growth of prostate carcinomas (4). Additionally, CHRM3 can effectively mediate the contractions of the mouse prostate elicited by acetylcholine (8). A great deal of attention has been focused on the roles of CHRM3 in prostate cancer, however, the signal transduction by CHRM3 in the pathophysiology of prostate cancer is not well understood. Therefore, investigation of the signal transduction by CHRM3 will herald a prominent expansion in our understanding of the molecular mechanisms of prostate cancer.

The microarray data of GSE3325 has been used to reveal critical genomic regions in the prostate tumor microenvironment for investigating novel biomarkers (9) or to reveal signatures of the metastatic progression of prostate cancer (10). In contrast to previous findings, the present study downloaded the GSE3325 microarray data and utilized comprehensive bioinformatics methods to identify the differentially-expressed genes (DEGs) associated with prostate cancer. Additionally, functional enrichment analysis of the DEGs was performed, and a protein-protein interaction (PPI) network and microRNA (miRNA)-target DEG network was constructed. The study aimed to elucidate the potential mechanisms used during signal transduction by CHRM3 in prostate cancer.

Materials and methods

Affymetrix microarray data

The microarray data of GSE3325 were downloaded from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/), based on the platform of GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array; Affymetrix Inc., Santa Clara, CA, USA). The gene expression files were deposited by Varambally et al (10). A total of 19 samples were applied to the development of the array data, including 6 benign, 7 clinically localized primary and 6 metastatic prostate cancer tissues. Each category contained 2 pooled samples. In order to better investigate the molecular pathogenesis of prostate cancer, pooled samples were discarded, and the expression profiles analyzed in this study were derived from 9 samples, including 5 clinically localized primary prostate cancer and 4 benign prostate tissues.

Data preprocessing and DEG screening

The raw data were first preprocessed by the robust multiarray average algorithm (11) with application of Affy package (12) in R language. The gene expression matrix of the samples was then acquired.

The DEGs in the primary prostate cancer tissues compared with the benign controls were screened by Limma package (13,14) in R language. The P-value was adjusted using Student's t-test (13) in Limma. Fold-change (FC) of the gene expression was also observed for differential-expression test. The DEGs with adjusted P-values <0.05 and |log2 FC| >1 were considered to be significant.

Gene Ontology (GO) and pathway enrichment analysis

The GO database (15) is a large-scale collection of gene annotation terms. The Kyoto Encyclopedia of Genes and Genomes (KEGG) (16) is a pathway-related database for classification of correlating gene sets into their respective pathways. The Database for Annotation Visualization and Integrated Discovery (DAVID) (17) is an online tool used for systematically associating the functional terms with large gene or protein lists.

In order to analyze the function of DEGs, GO annotation associated with biological process (BP) and KEGG pathway enrichment analysis of DEGs by DAVID online tool were performed. P<0.05 and gene counts >2 were set as the threshold.

PPI network construction

The Search Tool for the Retrieval of Interacting Genes (STRING) (18) is an online database that provides comprehensive information on predicted and experimental interactions of proteins in a given cell. The interactions of protein pairs are displayed with a combined score. In the present study, the DEGs were mapped into the STRING database to construct a PPI network with a combined score of protein pairs of >0.4 as the cut-off value. In addition, the connectivity degree of each node in the PPI network was calculated and the hub node was then identified (19).

Prediction of miRNAs associated with DEGs

The Web-based Gene Set Analysis Toolkit (WebGestalt) (20) is a web-based integrated system for analyzing large-scale gene sets in various functional categories, such as transcription factor and miRNA targets. In order to screen the potential miRNAs associated with DEGs, the DEG lists were uploaded to the WebGestalt system, and a miRNA-target DEG analysis was performed by WebGestalt. Enriched gene counts of ≥2 and rawP<0.05 were defined as the cut-off value.

Then miRNA-target DEG network composed of miRNAs and their target DEGs was visualized in the application of Cytoscape (21) software.

Integration of PPI network and miRNA-target DEG network

In the present study, the miRNA-target DEGs and PPI networks were further integrated, and the PPI pair-miRNA network composed of miRNAs and their target protein pairs was established with Cytoscape (21) software.

Results

DEG screening

Using the cut-off value of adjusted P-values <0.05 and |log2 FC| >1, a total of 224 DEGs in the primary prostate cancer tissues compared with the benign controls were screened, including 113 upregulated and 111 downregulated genes.

GO and pathway enrichment analysis

GO and pathway analyses were performed for the upregulated and downregulated genes, respectively. The overrepresented GO-BP terms of the upregulated DEGs were mainly associated with amine transport, amino acid transport and the enzyme-linked receptor protein signaling pathway (Table I). The downregulated DEGs were mainly involved in the regulation of cell proliferation, the response to organic substances and the negative regulation of the nitrogen compound metabolic process (Table II).

Table I.

GO-BP terms and KEGG pathways enriched by upregulated genes.

Table I.

GO-BP terms and KEGG pathways enriched by upregulated genes.

A, GO-BP terms

TermDescriptionCountP-value
GO:0015837Amine transport5 5.95×10−3
GO:0006865Amino acid transport4 1.78×10−2
GO:0007167Enzyme-linked receptor protein signaling pathway7 1.85×10−2
GO:0051674Localization of cell6 4.03×10−2
GO:0048870Cell motility6 4.03×10−2
GO:0035239Tube morphogenesis4 4.32×10−2
GO:0001501Skeletal system development6 4.62×10−2
GO:0035295Tube development5 4.63×10−2

B, Enriched KEGG pathways

TermDescriptionCountP-value

hsa04012ErbB signaling pathway3 8.21×10−2
hsa05216Thyroid cancer2 1.48×10−1
hsa00512O-glycan biosynthesis2 1.53×10−1
hsa04514CAMs3 1.64×10−1
hsa00071Fatty acid metabolism2 1.99×10−1
hsa05219Bladder cancer2 2.08×10−1
hsa05213Endometrial cancer2 2.51×10−1
hsa05221Acute myeloid leukemia2 2.75×10−1
hsa03320PPAR signaling pathway2 3.19×10−1
hsa04810Regulation of actin cytoskeleton3 3.33×10−1
hsa04350TGF-β signaling pathway2 3.84×10−1
hsa04060Cytokine-cytokine receptor interaction3 4.27×10−1
hsa05200Pathways in cancer3 5.48×10−1
hsa04310Wnt signaling pathway2 5.71×10−1
hsa04144Endocytosis2 6.45×10−1
hsa04510Focal adhesion2 6.78×10−1
hsa04080Neuroactive ligand-receptor interaction2 7.66×10−1
hsa04010MAPK signaling pathway2 7.80×10−1
hsa04740Olfactory transduction2 8.86×10−1

[i] Term, identification number of GO term or KEGG pathway; Description, name of GO term or KEGG pathway; Count, number of genes enriched in GO term or KEGG pathway; GO, Gene Oncology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CAMs, cell adhesion molecules; MAPK, mitogen-activated protein kinase; TGF-β, transforming growth factor-β; PPAR, peroxisome proliferator-activated receptor.

Table II.

Top 10 GO-BP terms and KEGG pathways enriched by downregulated genes.

Table II.

Top 10 GO-BP terms and KEGG pathways enriched by downregulated genes.

A, GO-BP terms

TermDescriptionCountP-value
GO:0042127Regulation of cell proliferation11 9.36×10−3
GO:0010033Response to organic substance  9 3.99×10−2
GO:0051172Negative regulation of nitrogen compound metabolic process  8 2.16×10−2
GO:0031327Negative regulation of cellular biosynthetic process  8 3.13×10−2
GO:0009890Negative regulation of biosynthetic process  8 3.45×10−2
GO:0044092Negative regulation of molecular function  7 9.21×10−3
GO:0008015Blood circulation  6 3.29×10−3
GO:0003013Circulatory system process  6 3.29×10−3
GO:0000122Negative regulation of transcription from RNA polymerase II promoter  6 1.44×10−2
GO:0045892Negative regulation of transcription, DNA-dependent  6 4.31×10−2

B, The enriched KEGG pathways

TermDescriptionCountP-value

hsa00982Drug metabolism3 3.14×10−2
hsa04360Axon guidance3 1.14×10−1
hsa00980Metabolism of xenobiotics by cytochrome P4502 2.39×10−1
hsa04512ECM-receptor interaction2 3.19×10−1
hsa04350TGF-β signaling pathway2 3.28×10−1
hsa04916Melanogenesis2 3.64×10−1
hsa04630Jak-STAT signaling pathway2 5.10×10−1
hsa04020Calcium signaling pathway2 5.56×10−1
hsa04510Focal adhesion2 6.05×10−1
hsa05200Pathways in cancer2 7.85×10−1

[i] Term, identification number of GO term or KEGG pathway; Description, name of GO term or KEGG pathway; Count, number of genes enriched in GO term or KEGG pathway. BP, biological process; GO, Gene Oncology; KEGG, Kyoto Encyclopedia of Genes and Genomes; TGF-β, transforming growth factor-β; ECM, extracellular matrix; Jak-STAT, Janus kinase-signal transducer and activator of transcription.

The upregulated DEGs were significantly enriched in the ErbB signaling pathway, thyroid cancer and O-glycan biosynthesis (Table I), while downregulated DEGs were significantly enriched in drug metabolism, axon guidance and metabolism of xenobiotics by cytochrome P450 (Table II). Notably, CHRM3 and epidermal growth factor (EGF) were significantly enriched in regulation of the actin cytoskeleton (Fig. 1). EGF and v-myc avian myelocytomatosis viral oncogene homolog (Myc) were enriched in the mitogen-activated protein kinase (MAPK) signaling pathway.

PPI network analysis

Based on the STRING database, a total of 27 upregulated PPIs (Fig. 2A) and 15 downregulated PPIs (Fig. 2B) with a combined score of >0.4 were obtained. The upregulated nodes with a connectivity degree of >2 were EGF (4), myoglobin (MB) (3), α-methylacyl-CoA racemase (3), early growth response 2 (3), fibromodulin (3) and activating transcription factor 3 (3). The downregulated node with a connectivity degree of >2 was peroxisome proliferator-activated receptor γ.

Prediction of miRNAs associated with DEGs

The miRNAs associated with DEGs were predicted by WebGestalt. A total of 11 upregulated miRNAs, including miR-23A, miR-23B, miR-219 and miR-143, and 4 downregulated miRNAs, including miR-193a, miR-193b, miR-124a and miR-302c, were selected (Table III). Notably, miR-34b could interact with Myc directly.

Table III.

Predicted miRNAs associated with DEGs.

Table III.

Predicted miRNAs associated with DEGs.

A, Upregulated

miRNACountP-value
hsa_GACAATC, miR-2195 1.10×10−3
hsa_TCATCTC, miR-1435 1.20×10−3
hsa_AATGTGA, miR-23a, miR-23b8 2.00×10−3
hsa_ACTGCCT, miR-34b5 6.20×10−3
hsa_AAGCAAT, miR-1375 6.30×10−3
hsa_GAGCCAG, miR-1494 7.60×10−3
hsa_TCTGATA, miR-3613 1.34×10−2
hsa_CATGTAA, miR-4964 1.41×10−2
hsa_GCAAGAC, miR-4312 2.33×10−2
hsa_TACTTGA, miR-26a, miR-26b5 2.33×10−2
hsa_CAGTGTT, miR-141, miR-200a5 2.61×10−2

B, Downregulated

miRNACountP-value

hsa_GGCCAGT, miR-193a, miR-193b3 1.11×10−2
hsa_TGCCTTA, miR-124a7 2.22×10−2
hsa_ATGTTAA, miR-302c4 3.31×10−2

[i] P-values are calculated from hypergeometric tests (rawP) and adjusted by the multiple test adjustment. Count, number of genes that interact with miRNAs; miRNAs, microRNAs; DEGs, differentially-expressed genes.

Integration of PPI and miRNA-target DEG networks

With Cytoscape software, the PPI and miRNA-target DEG networks were successfully integrated together. The upregulated and downregulated PPI pair-miRNA networks with significant protein pairs and their corresponding miRNAs were also established (Fig. 3).

Discussion

In the present study, the bioinformatics approach was used to investigate the potential mechanisms used during signal transduction by CHRM3 in prostate cancer. The results showed that CHRM3 and EGF were significantly enriched in regulation of actin cytoskeleton. EGF and Myc were enriched in the MAPK signaling pathway. Notably, as shown in Fig. 1, the activation of the regulation of the actin cytoskeleton may induce the activation of MAPK signaling pathway to a certain extent, thus promoting the progression of prostate cancer. Therefore, these DEGs and the aforementioned two pathways may be potential mechanisms during signal transduction by CHRM3 in prostate progression.

EGF, with the highest degree of connectivity, was the hub protein in the PPI network. Growth factors (GFs), including EGF, and their transmembrane receptor tyrosine kinases (RTKs) play important roles in the growth, proliferation, migration and differentiation of various human tumor cells (22,23). The EGF receptor (EGFR) family of RTKs is formed by four members: EGFR/ErbB1, human epidermal growth factor (HER)2/ErbB2, HER3/ErbB3 and HER4/ErbB4 (24). Increased expression and/or amplification of EGFR and HER2 have been recorded in a range of human cancer types (24). Additionally, stimulation with EGF results in the activation of the lipoprotein kinase, phosphatidylinositol 3-kinase (PI3K), which phosphorylates phosphatidylinositol 4,5-bisphosphate, generating the second messenger phosphatidylinositol (3,4,5)-trisphosphate (25). PI3K-Akt signaling pathway activation promotes prostate cancer cell metastasis and invasion (26,27). In the present study, the PI3K-Akt signaling pathway activated by EGF was a part of the regulation of the actin cytoskeleton. Therefore, the present results are in line with previous findings and suggest that EGF may play roles in the metastasis and invasion of prostate cancer via regulation of the actin cytoskeleton.

Furthermore, EGFR and HER2 have been identified to be essential pathway elements in the signaling from G protein-coupled receptors (GPCRs) (24). CHRM3 belongs to the GPCRs and is coupled to MAPK via EGFR (28). GPCRs may interact with Rho guanosine triphosphatases, including RhoA and Cdc42, which play roles in regulating cell motility (29). Moreover, GPCRs can induce EGFR transactivation, thus generating signals defining the required biological response (24). The roles of EGFR are as aforementioned. In addition, previous findings have strongly linked the excessive activation of the GPCR and RTK pathways to prostate cancer metastasis (26). Therefore, as shown in Fig. 1, CHRM3 may activate the regulation of the actin cytoskeleton via EGFR or GPCRs for the promotion of the metastasis of prostate cancer.

Notably, the highly-conserved MAPK signaling pathway can be activated by EGFR (22,24,30). Previous studies have also suggested that the activation of the MAPK cascade can be mediated by GPCRs via several distinct pathways (31). Moreover, the MAPK signaling pathway may be activated by means of a PI3K-dependent feedback loop in human cancer (32). The PI3K/Akt/mTOR and MAPK signaling pathways are often observed in prostate tumors (33). Therefore, CHRM3 may be further involved in the MAPK signaling pathway via the roles of EGFR or the activation of the PI3K-Akt signaling pathway. Additionally, MAPK signaling pathway activation is necessary for inhibitor of DNA binding 1-induced serum-independent prostate cancer cell growth (34). Targeting MAPK signaling pathway activated by AKT/mTOR and MEK/ERK can inhibit the progression of prostate cancer in humans (35). Taken together, these results and the present study results suggest that CHRM3 may play important roles in prostate cancer progression via activating the MAPK signaling pathway.

In addition to EGF, Myc was found to be significantly enriched in the MAPK signaling pathway in the present study. Myc is a basic helix-loop-helix leucine zipper transcriptional factor that functions in cell proliferation, differentiation and death (36). An increased Myc gene copy number is found in human prostate cancer, and Pim-1 kinase can cooperate with Myc in tumorigenesis (37). c-Myc may link v-ets avian erythroblastosis virus E26 oncogene homolog to a major oncogenic pathway in prostate cancer (38). In addition, Myc could interact with miR-34b directly in the present study. miR-34 mediates androgen receptor-dependent p53-induced apoptosis in prostate cancer (39). The study by Corney et al confirmed that miR-34b is a target of p53 and plays important roles in the control of cell proliferation (40). Furthermore, the MAPK/heterogeneous nuclear ribonucleoprotein K pathway controls the oncogenic potential of breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) oncoprotein via the regulation of Myc mRNA translation (41). Therefore, Myc may play an important role in prostate cancer via the MAPK signaling pathway, and the present results are consistent with the findings that the MAPK signaling pathway may be the key mechanism used during signal transduction by CHRM3 in prostate cancer.

In conclusion, EGF and Myc may play significant roles in the progression of prostate cancer via regulation of the actin cytoskeleton and the MAPK signaling pathway. CHRM3 may activate these two pathways via EGFR or GPCRs in prostate cancer progression. Thus, regulation of the actin cytoskeleton, the MAPK signaling pathway and the two key factors of EGF and Myc may be crucial mechanisms during signal transduction by CHRM3 in prostate cancer. The present findings shed new light on the molecular mechanism of prostate cancer and have implications for future research. However, a relatively small sample size and no experimental validation are limitations to the present study, and further genetic studies are required to confirm these observations.

Acknowledgements

The present study was supported by the Doctoral Fund of the Ministry of Education of China (grant no. 20120131120070).

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK and Shah GV: Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate. 30:160–166. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Witte LP, Chapple CR, de la Rosette JJ and Michel MC: Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol. 54:326–334. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Shah N, Khurana S, Cheng K and Raufman J-P: Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol. 296:C221–C232. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Ventura S, Pennefather J and Mitchelson F: Cholinergic innervation and function in the prostate gland. Pharmacol Ther. 94:93–112. 2002. View Article : Google Scholar : PubMed/NCBI

8 

White CW, Short JL, Haynes JM, Matsui M and Ventura S: Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors. J Pharmacol Exp Ther. 339:870–877. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Ashida S, Orloff MS, Bebek G, Zhang L, Zheng P, Peehl DM and Eng C: Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin Cancer Res. 18:1578–1587. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 8:393–406. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Gautier L, Cope L, Bolstad BM and Irizarry RA: Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article 3. 2004.PubMed/NCBI

14 

Smyth GK: Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry R and Huber W: (New York, NY). Springer. 397–420. 2005. View Article : Google Scholar

15 

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: The Gene Ontology Consortium: Gene ontology: Tool for the unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI

16 

Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI

17 

Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI

18 

von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: A database of predicted functional associations between proteins. Nucleic Acids Res. 31:258–261. 2003. View Article : Google Scholar : PubMed/NCBI

19 

He X and Zhang J: Why do hubs tend to be essential in protein networks? PLoS Genet. 2:e882006. View Article : Google Scholar : PubMed/NCBI

20 

Zhang B, Kirov S and Snoddy J: WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33(Web Server): W741–8. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI

23 

Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Bjorge JD, Chan T-O, Antczak M, Kung H-J and Fujita DJ: Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Proc Natl Acad Sci USA. 87:3816–3820. 1990. View Article : Google Scholar : PubMed/NCBI

26 

Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF and Tu Y: Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene. 28:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI and Gupta S: Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 121:1424–1432. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Slack BE: The m3 muscarinic acetylcholine receptor is coupled to mitogen-activated protein kinase via protein kinase C and epidermal growth factor receptor kinase. Biochem J. 348:381–387. 2000. View Article : Google Scholar : PubMed/NCBI

29 

Nie D, Guo Y, Yang D, Tang Y, Chen Y, Wang MT, Zacharek A, Qiao Y, Che M and Honn KV: Thromboxane A2 receptors in prostate carcinoma: Expression and its role in regulating cell motility via small GTPase Rho. Cancer Res. 68:115–121. 2008. View Article : Google Scholar : PubMed/NCBI

30 

Katz M, Amit I and Yarden Y: Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 1773:1161–1176. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Naor Z, Benard O and Seger R: Activation of MAPK cascades by G-protein-coupled receptors: The case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab. 11:91–99. 2000. View Article : Google Scholar : PubMed/NCBI

32 

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 118:3065–3074. 2008.PubMed/NCBI

33 

Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, et al: B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 72:4765–4776. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Ling M-T, Wang X, Ouyang X-S, Lee TK, Fan TY, Xu K, Tsao SW and Wong YC: Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene. 21:8498–8505. 2002. View Article : Google Scholar : PubMed/NCBI

35 

Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, et al: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 118:3051–3064. 2008.PubMed/NCBI

36 

Grandori C, Cowley SM, James LP and Eisenman RN: The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 16:653–699. 2000. View Article : Google Scholar : PubMed/NCBI

37 

Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV and Sawyers CL: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 4:223–238. 2003. View Article : Google Scholar : PubMed/NCBI

38 

Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, et al: TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 27:5348–5353. 2008. View Article : Google Scholar : PubMed/NCBI

39 

Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA and Cohen MB: MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther. 7:1288–1296. 2008. View Article : Google Scholar : PubMed/NCBI

40 

Corney DC, Flesken-Nikitin A, Godwin AK, Wang W and Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67:8433–8438. 2007. View Article : Google Scholar : PubMed/NCBI

41 

Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, et al: A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 107:2507–2516. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January-2016
Volume 11 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo L, Liu Y, Ding Z, Sun W and Yuan M: Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer. Oncol Lett 11: 385-392, 2016.
APA
Guo, L., Liu, Y., Ding, Z., Sun, W., & Yuan, M. (2016). Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer. Oncology Letters, 11, 385-392. https://doi.org/10.3892/ol.2015.3830
MLA
Guo, L., Liu, Y., Ding, Z., Sun, W., Yuan, M."Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer". Oncology Letters 11.1 (2016): 385-392.
Chicago
Guo, L., Liu, Y., Ding, Z., Sun, W., Yuan, M."Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer". Oncology Letters 11, no. 1 (2016): 385-392. https://doi.org/10.3892/ol.2015.3830